Technical Analysis for ARRY - Array BioPharma Inc.

Grade Last Price % Change Price Change
grade A 16.5 0.92% 0.15
ARRY closed up 0.92 percent on Friday, March 23, 2018, on 58 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ARRY trend table...

Date Alert Name Type % Chg
Mar 23 50 DMA Support Bullish 0.00%
Mar 23 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 23 Stochastic Reached Oversold Weakness 0.00%
Mar 23 Strong but Oversold Other 0.00%
Mar 23 Wide Bands Range Expansion 0.00%
Mar 23 Oversold Stochastic Weakness 0.00%
Mar 22 Lower Bollinger Band Walk Weakness 0.92%
Mar 22 Strong but Oversold Other 0.92%
Mar 22 Outside Day Range Expansion 0.92%
Mar 22 Wide Bands Range Expansion 0.92%

Older signals for ARRY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Is ARRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.78
52 Week Low 6.73
Average Volume 3,977,557
200-Day Moving Average 11.7651
50-Day Moving Average 16.3542
20-Day Moving Average 17.4775
10-Day Moving Average 17.027
Average True Range 0.752
ADX 22.89
+DI 16.62
-DI 20.89
Chandelier Exit (Long, 3 ATRs ) 16.524
Chandelier Exit (Short, 3 ATRs ) 18.336
Upper Bollinger Band 18.7426
Lower Bollinger Band 16.2124
Percent B (%b) 0.11
BandWidth 14.476899
MACD Line 0.0052
MACD Signal Line 0.2762
MACD Histogram -0.2709
Fundamentals Value
Market Cap 2.83 Billion
Num Shares 171 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -22.92
Price-to-Sales 41.12
Price-to-Book 153.97
PEG Ratio -1.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.76
Resistance 3 (R3) 17.81 17.43 17.55
Resistance 2 (R2) 17.43 17.11 17.41 17.48
Resistance 1 (R1) 16.97 16.91 17.20 16.92 17.41
Pivot Point 16.59 16.59 16.71 16.57 16.59
Support 1 (S1) 16.13 16.27 16.36 16.08 15.59
Support 2 (S2) 15.75 16.07 15.73 15.52
Support 3 (S3) 15.29 15.75 15.45
Support 4 (S4) 15.24